Making best practice, everyday practice

Login Register

Managing anticoagulation in cancer-associated thrombosis

Recent pivotal studies have resulted in revised guidelines for cancer patients with venous thromboembolism, which now recommends rivaroxaban and edoxaban as first choice for patients at low risk of bleeding.

Read below to complete the CPD questions Managing anticoagulation in cancer-associated thrombosis

 

CLICK ABOVE TO READ THE REPORT
WATCH THE ACCREDITED VIDEO AND READ THE SUMMARY REPORT

 

Do you like this? Share with a colleague